CN Patent

CN110407819B — 一种作为预防外科手术并发症的凝血酶受体拮抗剂

Assigned to Mudanjiang Medical University · Expires 2020-06-26 · 6y expired

What this patent protects

提供一种沃拉帕沙衍生物及其制备方法，所述化合物的结构如式I所示，其中R 1 选自氢、卤素、C1‑5烷基、氟代C1‑5烷基；所述化合物具有优异的PAR‑1抑制活性，尤其适用外科手术中预防并发症的出现，也有望替代沃拉帕沙成为一种有潜力的治疗心肌梗死、冠状动脉疾病的新药。

USPTO Abstract

提供一种沃拉帕沙衍生物及其制备方法，所述化合物的结构如式I所示，其中R 1 选自氢、卤素、C1‑5烷基、氟代C1‑5烷基；所述化合物具有优异的PAR‑1抑制活性，尤其适用外科手术中预防并发症的出现，也有望替代沃拉帕沙成为一种有潜力的治疗心肌梗死、冠状动脉疾病的新药。

Drugs covered by this patent

Patent Metadata

Patent number
CN110407819B
Jurisdiction
CN
Classification
—
Expires
2020-06-26
Drug substance claim
No
Drug product claim
No
Assignee
Mudanjiang Medical University
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.